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Summary 
Congenital insensitivity to pain with anhidrosis (CIPA) is characterized by recurrent 
episodes of unexplained fever, anhidrosis (inability to sweat), absence of reaction to 
noxious stimuli, self-mutilating behavior, and mental retardation. Human TRKA 
encodes a high-affinity tyrosine kinase receptor for nerve growth factor (NGF), a 
member of the neurotrophin family that induces neurite outgrowth and promotes 
survival of embryonic sensory and sympathetic neurons. We have recently 
demonstrated that TRKA is responsible for CIPA by identifying three mutations in a 
region encoding the intracellular tyrosine kinase domain of TRKA in one Ecuadorian 
and three Japanese families. We have developed a comprehensive strategy to screen for 
TRKA mutations, on the basis of the gene’s structure and organization. Here we report 
11 novel mutations, in seven affected families. These are six missense mutations, two 
frameshift mutations, one nonsense mutation, and two splice-site mutations. Mendelian 
inheritance of the mutations is confirmed in six families for which parent samples are 
available. Two mutations are linked, on the same chromosome, to Arg85Ser and 
His598Tyr; Gly607Val), hence, they probably represent double and triple mutations. 
The mutations are distributed in an extracellular domain, involved in NGF binding, as 
well as the intracellular signal-transduction domain. These data suggest that TRKA 
defects cause CIPA in various ethnic groups.
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Introduction 
Congenital insensitivity to pain with anhidrosis (CIPA: MIM 256800) is a rare autosomal 
recessive disorder characterized by recurrent episodes of unexplained fever, anhidrosis 
(inability to sweat), absence of reaction to noxious stimuli, self-mutilating behavior, and 
mental retardation (Swanson 1963; Dyck 1984; McKusick 1994). CIPA is also known as 
“congenital sensory neuropathy with anhidrosis,” “hereditary sensory and autonomic 
neuropathy type IV,” and “familial dysautonomia type II.” In CIPA, there is a lack of pain 
sensation, most likely the result of the absence of the dorsal root ganglia responsible for pain 
sensation. A feature of CIPA is the absence of small-diameter afferent neurons, which are 
activated by tissue-damaging stimuli (Swanson et al. 1965; Rafel et al. 1980). A loss of 
innervation of eccrine sweat glands, by sympathetic neurons, explains the phenomenon of 
anhidrosis (Langer et al. 1981; Ismail et al. 1998). Previously, the diagnosis of CIPA was 
established on the basis of clinical findings, pharmacological tests, and peripheral nerve 
biopsy. 
 Nerve growth factor (NGF) is the first growth factor to be identified and characterized 
(Levi-Montalcini 1987). Cell survival, growth, and differentiation in the nervous systems are 
mediated by numerous growth factors, including neurotrophic factors (neurotrophins). NGF 
supports the survival of sympathetic ganglion neurons and nociceptive sensory neurons in 
dorsal root ganglia, derived from the neural crest, and ascending cholinergic neurons of the 
basal forebrain (Levi-Montalcini 1987; Thoenen and Barde 1980). TRKA (also named 
NTRK1) was isolated from a colon carcinoma as a potential new member of the tyrosine 
kinase gene family (Martin-Zanca et al. 1986) and was later found to be expressed in the 
nervous system (Martin-Zanca et al. 1990). TRKA is a receptor tyrosine kinase that is 
phosphorylated in response to NGF (Kaplan et al. 1991; Klein et al. 1991). A single 
transmembrane domain divides TRKA into an extracellular domain, important for NGF 
binding, and an intracellular tyrosine kinase domain, important for signal transduction.  
 Mice lacking the orthologous gene of human TRKA share dramatic phenotypic features of 
CIPA, including loss of responses to painful stimuli, although anhidrosis is not apparent in 
these animals (Smeyne et al. 1994; Snider 1994). In addition, all dorsal root ganglia neurons 
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associated with nociceptive functions are lost in the deficient mice. They also have extensive 
neural cell loss in sympathetic ganglia and a decrease in cholinergic neurons of the basal 
forebrain. We therefore considered human TRKA as a candidate gene for CIPA. We 
identified the genetic basis for this disorder by showing that mutations in TRKA are 
associated with the absence of functional high-affinity NGF receptors in four patients (Indo 
et al. 1996). We focused on the region encoding the intracellular domain, since the whole 
structure of human TRKA was not known. CIPA is the first human genetic disorder 
implicated in the neurotrophin-signal-transduction system. The anomalous pain and 
temperature sensation in CIPA is probably because of a dramatic loss of unmyelinated 
C-fibers and small-diameter myelinated A-fibers in the afferent neurons. The NGF-TRKA 
system has a crucial role in the development and function of nociception, as well as the 
establishment of thermoregulation via sweating in humans.  
 Human TRKA maps to chromosome 1q (Miozzo et al. 1990; Morris et al. 1991). Recently, 
we and others independently determined the structure and organization of human TRKA 
(Greco et al. 1996; Indo et al. 1997; GenBank). We have established a method to amplify and 
analyze all coding exons from genomic DNA. This study describes the analysis of TRKA 
mutations in seven families from various ethnic groups, including nine CIPA patients, by 
direct sequencing of all exons and reports the detection of 11 novel mutations. The mutations 
responsible for CIPA are distributed in the extracellular domain, important for NGF binding, 
as well as in the intracellular domain, important for signal transduction. These data suggest 
that TRKA mutations cause CIPA in various ethnic groups and give insight into the structure 
and function relationship of the neurotrophin receptor tyrosine kinase family. 
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Patients and Methods 
  
Patients 
 Seven affected families, including nine patients with CIPA, were studied: two each are 
from Kuwait (KI-103 and KI-105) and Italy (KI-106 and KI-107); and one each from United 
Arab Emirates (KI-102), Spain (KI-104), and Canada (KI-108). All patients had 
characteristic features of CIPA, insensitivity to pain and anhidrosis. Lack of eccrine 
sweat-gland innervation was confirmed in KI-103 patient (Ismail et al. 1998). Parents were 
consanguineous in KI-102, -103, -104, -105, and -106. Affected individuals were diagnosed 
with CIPA on the basis of clinical findings or by pharmacological and pathological analyses. 
We also studied parents (obligate carriers) and sibling(s) in all families, except one. DNA 
samples of parents from family KI-107 were not available for testing. At least 50 unaffected 
Japanese individuals were screened to verify that the mutations found in patients with CIPA 
were absent in the normal population. DNA samples for all patients with CIPA, their family 
members, and normal individuals were obtained from peripheral blood leukocytes by 
standard methods. Blood was collected from patients with CIPA and family members, who 
were referred to the investigators, after giving informed consent.  
 
PCR Amplification of TRKA Exons and Sequencing 
 TRKA exons were amplified from genomic DNA by use of specific primers, derived from 
the 5’ and 3’ intronic or exonic sequences (table 1), and AmpliTaq (PE Applied Biosystems) 
or Expand Long Template PCR (Boehringer-Mannheim). The annealing temperature for each 
pair of primers was 54 - 62°C. A microsatellite (D1S506) is located in intron 12. Two or 
three consecutive exons: (i.e., 2 and 3; 5 and 6; 9, 10, and 11; and 13 and 14) were amplified 
simultaneously. The corresponding PCR products were purified by Microcon 100 (Millipore) 
or by agarose gel electrophoresis and QIAEX II Gel Extraction kit (QIAGEN). Direct 
sequencing of PCR products was performed with dRhodamine Terminator Cycle Sequencing 
Kit (PE Applied Biosystems). Sequences were resolved and analyzed on an ABI PRISM 310 
Genetic Analyzer (PE Applied Biosystems). Amplified segments were sequenced directly or 
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were subcloned into the T-vector, in the case of a compound heterozygote in which there 
were two different mutations. The plasmid vector, pBluescript KS (+) (Stratagene), was 
digested with EcoRV and treated with Taq polymerase (Marchuk et al. 1991). Sequence was 
determined as described above. Detected mutations were described according to a 
nomenclature system for human gene mutations (Antonarakis 1998). 
 
Restriction-Digestion Analysis 
   For analysis of the KI-102 family, genomic DNA was amplified with a set of primers, 
gTRKA(5+6)F and TRKA-L600. PCR products were digested with MvaI and 
electrophoresed. Conditions for PCR are described above. For analysis of family KI-104, 
PCR products, amplified with a set of primers for exon 15, were digested with MspI. The 
products were incubated with each restriction enzyme and electrophoresed on a 4% NuSieve 
agarose gel (FMC BioProducts).  
 
Exon Trapping System 
 An Exon Trapping System (GIBCO BRL) was used to confirm putative splice-site 
mutations in vitro, according to the manufacturer's protocol. For a mutation on the 
splice-acceptor site of intron 4, a 1.4-kb fragment, containing exons 4 and 5, was amplified 
with a set of primers -forward, gTRKA(4)F and reverse gTRKA(5)R - each from the patient 
or control. For a mutation on the splice-donor site of intron 7, a 2.6-kb fragment, containing 
exons 7 and 8, was amplified with a set of primers - forward, gTRKA(7)F and reverse, 
gTRKA(8)R - each from the patient or control. Amplified products were cloned into the 
T-vector and sequenced as described above. Subsequently, a XhoI-BamHI fragment, 
containing the insert from each clone, was subcloned into an exon trapping vector, pSPL3 
(GIBCO BRL). The pSPL3 derivatives were propagated in Escherichia coli, and the DNA 
was then isolated and transfected into COS-1 cells by Lipofectamin (GIBCO BRL). The 
following day, cells were harvested and RNA isolated. To characterize a DNA segment 
trapped as an exon, mRNAs were amplified by RT-PCR, by use of random hexamer (for 
reverse transcription) and a set of primers, to locate corresponding exons of TRKA. Primer set 
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SD6, in the pSPL3-vector sequence, and TRKA-L600, in exon 5, were used for detection of 
exon 5, whereas primer set TRKA-U842, in exon 7, and TRKA-L1144, in exon 8, were used 
for detection of exon 7. We also performed RT-PCR analysis of the E2 gene of 
branched-chainα -keto-acid-dehydrogenase complex, as a positive control, to demonstrate 
the integrity of the mRNA and reverse transcription. A set of primers, E2-4/E2-7, for E2, was 
described elsewhere (Tsuruta et al. 1998). 
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Results 
 
Physical Characteristics of a Patient with CIPA 
 We present a patient, to describe the physical characteristics associated with this disorder 
(fig.1). The patient is a 5-year-old white girl of mixed Czech and English-German ancestry, 
born to non-consanguineous parents. There are no abnormalities of the hair, eyebrows, or 
eyelashes (fig. 1A). She presents with recurrent unexplained fevers and anhidrosis by history. 
She developed palmoplantar hyperkeratosis, with significant fissuring of the plantar skin (fig. 
1B, C). Since a very young age, she has demonstrated self-mutilating behavior (avulsion of 
teeth, biting of distal extremities), and she has had several deep heel ulcers that take a long 
time to heal, yet are painless (fig. 1C). The mutations in this patient are described below 
(family KI-108).  
 
Mutations in TRKA in CIPA Families 
 Seven unrelated CIPA families were screened for mutations in the TRKA gene. These 
include nine patients, four normal siblings, and 12 obligate carriers. All 17 exons of the 
TRKA gene, including their flanking intronic sequences, were amplified from the genomic 
DNA of each patient with CIPA by use of the PCR primers, specified in table 1. All exons 
and intron-exon boundaries were sequenced. We detected putative mutation(s) in the proband. 
For missense mutations, we compared DNA sequences from 100 nonaffected chromosomes 
to reduce the likelihood that the described change represented a polymorphism. 
 In a male patient with CIPA, of family KI-102, sequencing of genomic DNA revealed that 
a 3’ splice site contained a G?C transversion in the first position of intron 4 (IVS4-1G?C; 
fig. 2A and table 2). The substitution destroys a restriction enzyme site for MvaI. Digestion 
analysis with this enzyme also demonstrated that the proband and parents were homozygous 
and heterozygous, respectively (fig. 2A). In addition, we detected a C?A transversion at 
nucleotide 337 in exon 2, which causes an Arg?Ser substitution at amino acid 85 
(Arg85Ser; table 2). Both parents were heterozygous for this substitution (data not shown). 
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 In family KI-103, a single base A at nucleotide 284 was deleted, in exon 1 of the two 
female patients (fig. 2B and table 2). The deletion (~284delA) causes a frameshift and 
premature termination codon after amino acid Asn 67 (Asn67fr). The patients and parents 
were homozygous and heterozygous, respectively. One of three male siblings with normal 
phenotype was wild type, and the other two were heterozygous for this deletion. Thus, 
~284delA is apparently the cause of CIPA in this family.  
 In family KI-104 we found a C?T transition, at nucleotide 2011 in exon 15 (~2011C?T), 
which causes an Arg?Trp substitution at amino acid 643 (Arg643Trp) (fig.2C and table 2). 
After amplification of exon 15 from parental genomic DNA, we detected mutant and 
wild-type alleles. The substitution destroys a restriction-enzyme site for MspI. Digestion 
analysis with this enzyme showed that the patient and parents were homozygous and 
heterozygous, respectively (fig. 2C).  
 In two female CIPA patients with CIPA, from family KI-105, a 5’ splice site of intron 7 
contained a G?A substitution in the first position (IVS7+1G?A) (fig. 2D and table 2). The 
proband and parents were homozygous and heterozygous for IVS7+1G?A, respectively. A 
female sibling with normal phenotype was heterozygous. 
 In family KI-106 we found a C?T transition at nucleotide 109 (109C?T) in exon 1, 
which changes a Gln to a termination codon at amino acid 9 (Gln9X) in the proband (fig. 2E 
[upper] and table 2). In addition, we detected two further base changes, both in exon 15: a 
C?T transition at nucleotide 1876 (~1876C?T) and a G?T transversion at nucleotide 1904 
(~1904G?T) which cause a His?Tyr substitution at amino acid 598 (His598Tyr) and a 
Gly?Val substitution at amino acid 607 (Gly607Val), respectively (data not shown). The 
proband and both parents were homozygous and heterozygous for all base substitutions, 
respectively.  
 In family KI-107 a homozygous G?A transition at nucleotide 2206 (~2206G?A), in 
exon 16, was predicted to cause a Gly?Ser substitution at amino acid 708 (Gly708Ser) (fig. 
2E [lower] and table 2). DNA samples from parents were not available for testing. 
 In family KI-108 the proband was a compound heterozygote, having two different 
mutations at the TRKA locus on separate chromosomes (fig. 2F and table 2). Each mutant 
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allele was subcloned into a plasmid vector and sequenced. One contained a 7-base deletion, 
from nucleotide 1008 to 1014 (~1008-1014delGCCGGCA) in exon 8, which is predicted to 
cause a frameshift after amino acid Gln308 and create of a downstream premature 
termination codon (Gn308fr). The other was a T?C transition at nucleotide 722 (~722T?C) 
in exon 6, which causes a Leu?Pro substitution at amino acid 213 (Leu213Pro). Sequence 
analysis of the parents revealed that (~1008-1014delGCCGGCA) and (~722T?C) were 
derived from the father and mother, respectively. 
 
Exon Trap Analysis of Splice-Site Mutations 
 We characterized the IVS4-1G?C mutation in family KI-102 and the IVS7+1G?A 
mutation in family KI-05 by using exon trap analysis, since mRNA preparations from the 
patient were not available for testing. A 1.4-kb fragment containing exons 4 and 5, or a 
2.6-kb fragment containing exons 7 and 8, as well as part of the flanking introns, was 
amplified from proband and control samples. Each was subcloned into the exon trap vector, 
pSPL3, to prepare a minigene construct. After transfection of the minigene and incubation of 
cells, we observed whether exon 5 or exon 7 was incorporated into a transcript. RT-PCR 
analysis demonstrated that the corresponding exon was incorporated in the control but not in 
the patient (fig. 3A, B). A faint, large DNA fragment was observed in the patient sample 
from family KI-102 (fig. 3A). Sequence analysis of the fragment showed that it was derived 
from an alternative splicing event, which occurred at a cryptic splice-acceptor site in intron 4 
(IVS4-41; data not shown). 
 Thus, 11 novel mutations have been detected in seven CIPA families from five countries. 
None of these mutations were detected in 100 chromosomes from unrelated controls. Further, 
all appear to be “private mutations”, restricted to each individual family. 
 10 
  11 
Discussion 
 
We reported elsewhere that TRKA is the gene responsible for CIPA (Indo et al. 1996). 
Given the lack of information on the structure of the entire human TRKA gene, we restricted 
our analysis to the region encoding the intracellular tyrosine kinase domain. We detected 
three mutations, R548fs, G571R, and IVS15+3A?C, in three consanguineous Japanese 
CIPA families and in one consanguineous Ecuadorian CIPA family. These mutations are 
located in exon 14 and intron 15 (fig. 4). It has not been confirmed whether all patients with 
CIPA have mutation(s) in TRKA or whether there is genetic heterogeneity among various 
ethnic groups. Complete analysis of patients with CIPA was hampered by the lack of 
full-length gene sequence; hence we reported on the structure and organization of the whole 
human TRKA, to facilitate mutation analysis (Indo et al. 1997).  
Human TRKA is divided into 17 exons and 16 introns. The entire sequence was estimated 
to span ≥ 23 kb, coding for a protein of 790 or 796 amino acid residues. A single 
transmembrane domain divides the TRKA protein into an extracellular and an intracellular 
domain (Schneider and Schweiger 1991; Barbacid 1995; Bothwell 1995). The extracellular 
domain is important for specific NGF binding and includes a signal peptide; three tandem 
leucine-rich motifs, flanked by two cysteine clusters; and two immunoglobulin-like domains 
(or motifs). The intracellular domain includes a juxtamembrane region, a tyrosine kinase 
domain, and a very short carboxyl-terminal tail. There is a general correlation between the 
genomic organization of TRKA and the functional organization of the TRKA protein product 
(fig 4) (Indo et al. 1997). Exon 1 contains the signal peptide and the first cysteine cluster. 
Three leucine-rich motifs are encoded by exons 2, 3 and 4. Exon 5 contains the second 
cysteine cluster. The first immunoglobulin-like motif is encoded by exons 6 and 7, whereas 
the second immunoglobulin-like motif is encoded by the single exon 8. Thus, the splice sites 
of TRKA, encoding the extracellular domain, separate the functional domains, so that each is 
encoded by separate exons. Exon 9 is small (18 bp) and incorporated into mRNA by 
alternative splicing. Six amino acid residues encoded by this exon are present in the 
extracellular domain of the neuronal-specific TRKA receptor (Barker et al. 1993). The 
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transmembrane domain is encoded by exons 10 and 11, and the intracellular domain of 
TRKA is encoded by exons 11-17. The juxtamembrane domain is encoded by exons 11 and 
12. The domain contains an IXNPXpY motif, where “p” indicates phosphorylation at the 
Tyr-490 residue of the activated TRKA (Dikic et al. 1995). This motif is encoded by exon 12 
and is recognized by an Shc-adapter protein, required for activation of the Ras-MAPK 
pathway (Obermeier et al. 1994; Stephens et al. 1994). The tyrosine kinase domain that is 
phosphorylated in response to NGF - and is critical for the intercellular signaling - is encoded 
by exons 13-17. A consensus sequence motif YXXM, which interacts with 
phosphatidylinositol-3’ kinase, is located at the end of the kinase catalytic domain (Tyr-751 
residue in TRKA) (Obermeier et al. 1993b; Soltoff et al. 1992) and encoded by exon 17. The 
short carboxyl-terminal tail of 15 amino acids is also encoded by exon 17 and includes a 
conserved Tyr residue (Tyr-785 in TRKA) that is responsible for binding of phospholipase 
Cγ (Obermeier et al. 1993a; Loeb et al. 1994). 
 In this report, we present the methodology to amplify and analyze all coding exons from 
genomic DNA by PCR-direct sequencing. A total of 11 novel mutations are described, in 
seven families from various ethnic groups (fig. 4). CIPA mutations are spread throughout the 
signal peptide, extracellular domain, and intracellular domain. These are six missense 
mutations (Arg85Ser, Leu213Pro, His598Tyr, Gly607Val, Arg643Trp, and Gly708Ser), two 
frameshift mutations (Asn67fs and Gln308fs), one nonsense mutation (Gln9X), and two 
splice mutations (IVS4-1G?C and IVS7+1G?A).  
 Three missense mutations, Leu213Pro, Arg643Trp, and Gly708Ser, are probably 
responsible for CIPA. They have not been observed in 100 normal chromosomes. The 
Leu213Pro mutation is detected in a state of compound heterozygosity in the patient who has 
a 7-base pair deletion on a separate chromosome. It is located in the first 
immunoglobulin-like motif in the extracellular domain, which is important for NGF binding, 
and is conserved between TRKA and TRKB. Both the Arg643Trp and Gly708Ser mutations 
are located in the intracellular tyrosine kinase domain and conserved among ≥ 14 receptor 
tyrosine kinases, including human TRKB and TRKC (Martin-Zanca et al. 1989; Nakagawara 
et al. 1995). This suggests that they are important for enzyme activity. Arg85Ser and 
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(His598Tyr and Gly607Val) are detected as a double and triple mutation, respectively, and 
described below. The His598Tyr is located in the intracellular tyrosine kinase domain and 
conserved in three TRK families. However, Arg85Ser (located in the leucine-rich motif of 
the extracellular domain) and Gly607Val (in the intracellular tyrosine kinase domain) are not 
conserved. The effects of all these missense mutations on the function of the TRKA protein 
are currently unknown, although experiments are in progress to address this question.  
 Two frameshift mutations, Asn67fs and Gln308fs, are located in the first cysteine cluster 
and the second immunoglobulin-like motifs, respectively. These should result in truncation 
of the TRKA polypeptide in the extracelluar domain. Thus, these two mutations almost 
certainly cause defects in NGF signal transduction.  
 The nonsense mutation, Gln9X, is located on the signal peptide and is associated with two 
missense mutations (His598Tyr and Gly607Val) on the same chromosome. The parents in 
this family are consanguineous, and both are carriers of these three mutations. The patient is 
homozygous for all three. Thus, they probably represent a triple mutation, although Gln9X is 
the most likely cause of CIPA in this family. Triple mutation is rare and has been reported in 
Gaucher disease (Hong et al. 1990). In contrast, double mutations have been reported in 
several clinically relevant genes, such as the gene encoding the α-subunit of hexosaminidase 
A (Ainsworth and Coulter-Mackie 1992), the low-density lipoprotein receptor (Jensen et al. 
1997), and so on. Without screening the entire coding regions of TRKA in the 
consanguineous homozygous patient, these CIPA mutations would not have been detected. 
The triple mutation awaits further study.  
 Two splice site mutations (IVS4-1G?C and IVS7+1C?A) cause skipping of exon 5 and 
exon 7, respectively, in vitro. We predict that IVS4-1G?C and IVS7+1G?A cause a skip of 
exon 5 or alternative splicing, and a skip of exon 7, respectively, in vivo. These exons are 
located in a region encoding the extracellular domain of TRKA. These changes would result 
in a deletion of the second cysteine cluster or a part of the first immunoglobulin-like motifs. 
Further, these two changes would result in a frameshift and cause a truncation of the TRKA 
protein. This structural change in the extracellular domain would affect the function of 
TRKA in NGF binding, and hence these splice mutations are probably responsible for CIPA. 
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In addition, the splice IVS4-1G?C mutation is associated with Arg85Ser on the same 
chromosome. The patient and both parents are homozygous and heterozygous for these two 
substitutions in this consanguineous family. Thus, these two probably represent a double 
mutation. The IVS4-1G?C is likely the main cause of CIPA in this family, considering the 
effect of exon skipping or alternative splicing. 
 The data presented in this article represent the first extensive mutation analysis of the 
whole TRKA gene in CIPA patients from various ethnic groups. Mendelian inheritance of the 
mutations was confirmed by sequence analysis of the relevant amplified DNA fragment in 
family members. These mutations do not seem to represent frequent polymorphisms because 
they are not detected in unaffected control individuals. We cannot completely rule out the 
possibility that they are rare polymorphisms. The three amino acid substitutions detected as 
double or triple mutations might be rare polymorphisms in a particular ethnic background. 
 Mutations responsible for CIPA are located in the extracellular domain as well as in the 
intracellular domain of TRKA. They provide insight into the structure and function, for 
neurotrophin members, of the TRK receptor family. We did not observe any 
genotype-phenotype correlation in the patients with CIPA we analyzed in this study. All 
patients have typical features: insensitivity to pain and anhidrosis. There seems to be no 
genetic heterogeneity in CIPA, although we cannot rule out the possibility that mutation(s) in 
other gene(s) are responsible for clinical phenotypes similar to CIPA.  
 CIPA is a painless but severe genetic disorder associated with devastating complications, 
often leading to crippling or fatal consequences. This study will facilitate analyses of CIPA 
mutations in TRKA and provide an invaluable aid for the diagnosis of this disorder and for 
genetic counseling. 
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Figures 
 
Figure 1 Physical characteristics of a patient with CIPA, a 5-year-old white girl 
born to non-consanguineous parents. 
 
Figure 1A, There are no abnormalities of the hair, eyebrows, or eyelashes.  
 
 
 
Figure 1A, There are no abnormalities of the hair, eyebrows, or eyelashes. 
Informed consent for publication of photographs was obtained from her parents. 
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Figure 1B, Palmer skin is dry and hyperkeratotic.  
 
 
 
Figure 1B, Palmer skin is dry and hyperkeratotic. 
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Figure 1C, Plantar skin is dry and hyperkeratotic, with significant fissuring.  
 
 
 
 
Figure 1C, Plantar skin is dry and hyperkeratotic, with significant fissuring. 
Deep heel ulcers are painless and slow to heal. 
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Figure 2 Mutation analysis of the human TRKA, in seven CIPA families. 
 
Figure 2A 
In family KI-02 a G?C transversion at the first position of the 3’ splice site in intron 4 
(IVS4-1G?C) (upper) and restriction-digestion analysis with MvaI (lower) are shown.  
 
Figure 2 Mutation analysis of the human TRKA, in seven CIPA families. 
Figure 2A, In family KI-02 a G?C transversion at the first position of the 3’ splice site in 
intron 4 (IVS4-1G?C) (upper) and restriction-digestion analysis with MvaI (lower) are 
shown. Shown are a normal control (lane 1), the patient (lane 2), and the patient’s father and 
mother (lanes 3 and 4). 
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Figure 2B 
A single base deletion at nucleotide 284 of exon 1, in family KI-103. 
 
 
 
Figure 2B, A single base deletion at nucleotide 284 of exon 1, in family KI-103. Reverse 
sequences are shown. Shown are a normal control (box 1); the proband, as a representative 
patient in this family (box 2); and the father, as a representative heterozygote (box 3). The 
proband and her young sister with CIPA are homozygous for the mutation. An older brother 
is normal. Two younger brothers with normal phenotype and both parents are heterozygous.  
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Figure 2C 
In family KI-104 a C?T transition at nucleotide 2011 in exon 15 (upper) and 
restriction-digestion analysis with MspI (lower) are shown. 
 
 
 
Figure 2C, In family KI-104 a C?T transition at nucleotide 2011 in exon 15 (upper) and 
restriction-digestion analysis with MspI (lower) are shown. The transition causes an 
Arg?Trp substitution at amino acid 643. Shown are a normal control (lane 1); the patient 
(lane 2); and the patient’s father and mother (lanes 3 and 4). 
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Figure 2D 
A G?A transition at the first position of the 5’ splice site in intron 7, in family KI-105.  
 
 
 
Figure 2D, A G?A transition at the first position of the 5’ splice site in intron 7, in family 
KI-105. Shown are a normal control (box 1); the proband, as a representative patient in this 
family (box 2); and the father, as a representative heterozygote (box 3). The proband and her 
younger sister with CIPA are homozygous for the mutation. Both parents and her younger 
sister with normal phenotype are heterozygous.   
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Figure 2E 
In family KI-106, a C?T transition at nucleotide 109 in exon 1 causes a Gln codon to 
become a termination codon at position 9, as shown in the upper part.  
 
 
 
Figure 2E, In family KI-106, a C?T transition at nucleotide 109 in exon 1 causes a Gln 
codon to become a termination codon at position 9, as shown in the upper part. Shown are a 
normal control (box 1), the patient (box 2), and the patient’s father and mother (boxes 3 and 
4). 
In family KI-107, a G?A transition at nucleotide 2206 in exon 16 causes a Gly?Ser 
substitution at amino acid 708, as shown in the lower part. DNA samples from parents were 
not available for testing in this family.  
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Figure 2F 
Two different mutations at the TRKA locus, in family KI-108.  
 
 
 
Figure 2F, Two different mutations at the TRKA locus, in the KI-108 family. 
A 7-base pair deletion, from nucleotide 1008 to 1014 in exon 8 (~1008-1014delGCCGGCA), 
causes a frameshift after amino acid Gln308 and premature termination codon downstream, 
as shown for control and subcloned mutant sequences, respectively (boxes 1 and 2). This 
mutation is derived from her father (box 3). The other, a T?C transition at nucleotide 722 in 
exon 6, causes a Leu?Pro substitution at amino acid 213; results of the PCR direct sequence 
are shown in reverse orientation for control and mutant sequences, respectively (boxes 4 and 
5). The latter mutation is derived from her mother (box 6). 
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Figure 3 Exon trap analysis of splice-site mutations in TRKA. 
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Figure 3. Exon trap analysis of splice site mutations in the TRKA gene. 
 
Figure 3A, Characterization of the IVS4-1G?C mutation detected in family KI-02. 
A fragment containing exons 4 and 5, as well as parts of flanking introns, was subcloned into 
the exon trap vector, pSPL3, and transfected into COS-1 cells. RT-PCR analysis was done on 
the mRNA from such cells transfected with each vector construct. Shown are a vector alone 
(lane 1), a vector with a normal TRKA gene (lane 2), a vector with a mutant TRKA gene (lane 
3), and PCR reaction without a product by reverse transcription (lane 4). Exon 5 is 
incorporated in the control but not in the patient. A 268-bp fragment was amplified from the 
normal construct (lane 2). Faint bands in lane 3 are products of alternative splicing, as 
described in the text. A housekeeping gene was analyzed, as a control for integrity of the 
mRNA and of the RT-PCR reaction. 
 
Figure 3B 
Characterization of the IVS7+1G?A mutation in family KI-05.  
Figure 3B, Characterization of the IVS7+1G?A mutation in family KI-05. A fragment 
containing exons 7 and 8, as well as parts of flanking introns, was used in a similar way, as 
described above. Exon 7 is incorporated in the control but not in the patient. A 323-bp 
fragment was amplified from the normal construct (lane 2). 
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Figure 4 Disease-associated mutations in TRKA.  
 
 
 
 
Figure 4. Disease-associated mutations in TRKA. Amino acid numbering of the TRKA 
protein and structure of the TRKA gene are according to Martin-Zanca et al. (1989) and Indo 
et al. (1997), respectively. Mutations reported in this study are listed above the TRKA 
diagram, and three mutations, previously reported, are listed below the diagram. A 
nomenclature system for human gene mutations is used according to the recommendations of 
Antonarakis (1998). Mutations in brackets are detected as double or triple mutations, as 
described in the text. Abbreviations listed in the lower part show the domain structures 
encoded by the corresponding exon(s) (Schneider and Schweiger 1991; Indo et al. 1997).  
SP = signal peptide; CC-1 and CC-2 = the first and second cysteine clusters, respectively; 
LRMs = leucine-rich motifs; Ig-1 and Ig-2 = the first and second immunoglobulin-like 
motifs, respectively; TM = transmembrane; JX = juxtamembrane; and TK = tyrosine kinase.  
 
 31 
Table 1
Primer Sequence Used for the TRKA Gene
PCR Product 
Analysis and Primer Name Exons Forward Reverse (bp)
PCR-Direct Sequence:
 gTRKA(1)F/R 1 AGCTGGGAGCGCACAGACGG CAGCAAACAAGCAGCGAGTC 323
 gTRKA(2+3)F/R 2+3 TGTGACTCCCATCCGCTCTC TGTCCTCCCCAACTCCCACT 516
 gTRKA(4)F/R 4 GCTCCTCCCCTCCCTCATTC GTCATCCAACAGACCCAAGT 224
 gTRKA(5+6)F/R 5+6 CTCCCTCTTATCCCCTGTGA CTTTGTCCCCTGTGCTCTGC 716
 gTRKA(7)F/R 7 CCTCCTCTCCTTTCCATCTG CACCCTACATCCTCTTTTGA 312
 gTRKA(8)F/R 8 TTCGGGTTCTACTCGCTTTG TGGGGGCAGGGTTCAGGATG 456
 gTRKA(9+10+11)F/R 9+10+11 CCAGCAGCCCACCTCCATCC TACCCCAAACACACTCACAC 895
 gTRKA(12)F/R 12 AGTTACAAGGTGGGGGTGAC GGGCCTATGGCTGGAA 388 *
 gTRKA(13+14)F/R 13+14 CAACCCCAGCCCTCCCAAGA CTATGTTCACACATCTGCCT 724
 gTRKA(15)F/R 15 CCAGTCTCCTCTCCCATCAC TGGGATCCAGGGTGTCTACA 406
 gTRKA(16)F/R 16 TAATGATGGGGCTGGGGTAG AGGCCAGCAAGGGGTGACCA 276
 gTRKA(17)F/R 17 GCTTTCTCCTCTGTCTCTCC ATTCCGGCTAACCACTCCCA 254
Restriction enzyme:
  gTRKA(5+6)F/TRKA-L600 5 (partial) CTCCCTCTTATCCCCTGTGA CATGACACTGCAGCTTCTGT 176
Exon trap:
 gTRKA(4)F/gTRKA(5)R 4+5 GCTCCTCCCCTCCCTCATTC TTTCAGTGCTTGCTCAGTGCC ~1,400
 gTRKA(7)F/gTRKA(8)R 7+8 CCTCCTCTCCTTTCCATCTG TGGGGGCAGGGTTCAGGATG ~2,600
 SD6/TRKA-L600 5 ( partial ) ATTTAGGTGACACTATAG CATGACACTGCAGCTTCTGT 268
 TRKA-U842/TRKA-L1144 7+8 ( partial ) ATGTCACCAGTGACCTCAAC GTGTAGTTGCCGTTGTTGAC 323
*Number  in which gt repeats of microsatellite D1S506 = 20.
Primer Sequence (5'-->3')
Table 2 
 Mutation Analysis of CIPA Families
Family Consanguinity Status Nucleotide Change* Mutation Type & Country of
(Location) (Predicted Consequence) Origin
KI-102 Yes Homozygote [ IVS4-1G>C; ~337C>A ] [Splice site;missense] UAE
(Intron 4; Exon 2) (Aberrant splicing of exon 5; Arg85Ser)
KI-103 Yes Homozygote ~284delA Frameshift Kuwait
(Exon 1) (Truncation after Asn67)
KI-104 Yes Homozygote ~2011C>T Missense Spain
(Exon 15) (Arg643Trp)
KI-105 Yes Homozygote IVS7+1G>A Splice site Kuwait
(Intron 7) (Aberrant splicing of exon 7)
KI-106 Yes Homozygote [ ~109C>T; ~1876C>T; ~1904G>T ] [Nonsense;  Missense; Missense] Italy
(Exon 1     ; Exon 15      ; Exon 15) (Gln9X; His598Tyr; Gly607Val)
KI-107 No Homozygote ~2206G>A Missense Italy
(exon 16) (Gly708Ser)
KI-108 No Compound ~722T>C  Missense (Leu213Pro) ; Canada*
heterozygote (Exon 6)
c.1008^1014delGCCGGCA Frameshift (Truncation after Gln308) 
(Exon 8)
Note. - Positions of nucleotide change are from the transcription start site, as described in Martin-Zanca et al.(1989)
 The ATG initiation codon is located at nucleotide position c85.
 The structure and organization of the human TRKA  was desribed by Indo et al.(1997).
* Family from Canada is of mixed Czech and English-German ancestry.
